

# Supporting Information

## Community-Associated *Staphylococcus aureus* from Sub-Saharan Africa and Germany: A Cross-Sectional Geographic Correlation Study

Ulla Ruffing<sup>1</sup>, Abraham Alabi<sup>2\*</sup>, Theckla Kazimoto<sup>3\*</sup>, Delfino C. Vubil<sup>4\*</sup>, Ruslan Akulenko<sup>5\*</sup>, Salim Abdulla<sup>3</sup>, Pedro Alonso<sup>4,6</sup>, Markus Bischoff<sup>1</sup>, Anja Germann<sup>7</sup>, Martin P. Grobusch<sup>2,8</sup>, Volkhard Helms<sup>5</sup>, Jonas Hoffmann<sup>9</sup>, Winfried V. Kern<sup>9</sup>, Peter G. Kremsner<sup>2,10</sup>, Inacio Mandomando<sup>4</sup>, Alexander Mellmann<sup>11</sup>, Georg Peters<sup>12</sup>, Frieder Schaumburg<sup>12</sup>, Sabine Schubert<sup>1</sup>, Lena Strauß<sup>11</sup>, Marcel Tanner<sup>3,13</sup>, Hagen von Briesen<sup>7</sup>, Laura Wende<sup>1</sup>, Lutz von Müller<sup>1</sup>, Mathias Herrmann<sup>1#</sup>

<sup>1</sup> Institute of Medical Microbiology and Hygiene, Saarland University, Homburg, Germany,

<sup>2</sup> Centre de Recherches Médicales de Lambaréné (CERMEL), Albert Schweitzer Hospital,

Lambaréné, Gabon; <sup>3</sup> Ifakara Health Research and Development Centre (IHRDC), Dar es

Salaam, Tanzania; <sup>4</sup> Manhiça Health Research Center, Manhiça, Mozambique; <sup>5</sup> Center for

Bioinformatics, Saarland University, Saarbrücken, Germany; <sup>6</sup> Department of Public Health,

University of Barcelona, Spain; <sup>7</sup> Fraunhofer Institute for Biomedical Engineering, St. Ingbert,

Germany; <sup>8</sup> Center of Tropical Medicine and Travel Medicine, Department of Infectious

Diseases, Division of Internal Medicine, University of Amsterdam, Amsterdam, The

Netherlands; <sup>9</sup> Division of Infectious Diseases and Travel Medicine, University of Freiburg,

Germany; <sup>10</sup> Institute of Tropical Medicine, University of Tübingen, Deutsches Zentrum für


Infektionsforschung, Tübingen, Germany; <sup>11</sup> Institute of Hygiene, University Hospital Münster,

Münster, Germany; <sup>12</sup> Institute of Medical Microbiology, University Hospital Münster, Münster,

Germany; <sup>13</sup> Swiss Tropical and Public Health Institute, Basel, Switzerland

\*second authors, equal contribution

# Corresponding author. Current address: University of Münster Medical Faculty, Domagkstr. 3, 48149 Münster, Germany, Phone: +49-251-8355491, Email: mathias.herrmann@uni-muenster.de



**Figure S1:** Phylogeny of *Staphylococcus aureus* from Africa and Germany. *S. aureus* (n=154) from colonization and infection were collected in Africa (red) and Germany (blue). The published whole genome sequencing data were used to construct a neighbor-joining tree (Strauss et al. Clin Microbiol. 2016 Apr;54(4):1008-16 ). Labels show the multilocus sequence types of each isolate.

Table S1: Microarray target recognition

		All Isolates					Clinical Isolates				
		German, n (%)	African, n (%)	OR	CI <sub>95</sub>	P	German, n (%)	African, n (%)	OR	CI <sub>95</sub>	P
Regulatory genes	sarA	599 (100)	600 (100)	n/a			300 (100)	300 (100)	n/a		
	saeS	600 (100)	600 (100)	n/a			300 (100)	300 (100)	n/a		
	vraS	600 (100)	599 (100)	n/a			300 (100)	300 (100)	n/a		
	<b>agrI total.</b>	<b>331 (55)</b>	<b>209 (35)</b>	<b>2.30</b>	<b>1.82-2.91</b>	<b>&lt;0.0001</b>	<b>179 (60)</b>	<b>99 (33)</b>	<b>3.00</b>	<b>2.15-4.19</b>	<b>&lt;0.0001</b>
	agrII.total	151 (25)	161 (27)	0.92	0.71-1.19	ns	179 (60)	99 (33)	0.83	0.57-1.21	<0.0001
	agrIII.total	84 (14)	93 (16)	0.89	0.65-1.22	ns	68 (23)	78 (26)	0.83	0.57-1.21	ns
	<b>agrIV.total</b>	<b>38 (6)</b>	<b>221 (37)</b>	<b>0.12</b>	<b>0.08-0.17</b>	<b>&lt;0.0001</b>	<b>36 (12)</b>	<b>50 (17)</b>	<b>0.10</b>	<b>0.06-0.16</b>	<b>ns</b>
Toxins	tst1..consensus	67 (11)	36 (6)	1.96	1.29-3.00	ns	23 (8)	12 (4)	1.9	0.97-4.08	ns
	sea	68 (11)	92 (15)	0.71	0.50-0.99	ns	28 (9)	44 (15)	0.60	0.36-0.99	ns
	<b>seb</b>	<b>45 (8)</b>	<b>114 (19)</b>	<b>0.35</b>	<b>0.24-0.50</b>	<b>&lt;0.0001</b>	<b>23 (8)</b>	<b>72 (24)</b>	<b>0.26</b>	<b>0.16-0.43</b>	<b>&lt;0.0001</b>
	<b>sec</b>	<b>92 (15)</b>	<b>49 (8)</b>	<b>2.07</b>	<b>1.41-2.94</b>	<b>0.02</b>	<b>57 (19)</b>	<b>19 (6)</b>	<b>3.47</b>	<b>2.01-5.99</b>	<b>0.001</b>
	<b>sed</b>	<b>52 (9)</b>	<b>21 (4)</b>	<b>2.62</b>	<b>1.56-4.40</b>	<b>0.03</b>	<b>35 (12)</b>	<b>9 (3)</b>	<b>4.27</b>	<b>2.02-9.05</b>	<b>0.01</b>
	see	1 (0)	0 (0)	n/a			1 (0)	0 (0)	n/a		ns
	seh	26 (4)	34 (6)	0.75	0.45-1.27	ns	12 (4)	18 (6)	0.65	0.31-1.38	ns
	sej	41 (7)	25 (4)	1.69	1.01-1.06	0.01.	27 (9)	10 (3)	2.87	1.37-6.04	ns
	sek	27 (5)	56 (9)	0.46	0.29-0.74	ns	14 (5)	27 (9)	0.50	0.25-0.96	ns
	<b>sel</b>	<b>92 (15)</b>	<b>50 (8)</b>	<b>1.99</b>	<b>1.38-2.87</b>	<b>0.03</b>	<b>57 (19)</b>	<b>20 (7)</b>	<b>3.28</b>	<b>1.92-5.62</b>	<b>0.002</b>
	<b>egc total</b>	<b>332 (55)</b>	<b>253 (42)</b>	<b>1.70</b>	<b>1.35-2.14</b>	<b>0.02</b>	<b>173 (58)</b>	<b>120 (40)</b>	<b>2.04</b>	<b>1.48-2.83</b>	<b>0.04</b>
	seq	27 (5)	56 (9)	0.46	0.29-0.74	ns	14 (5)	27 (9)	0.50	0.25-0.96	ns
	ser	37 (6)	20 (3)	1.91	1.09-3.32	ns	24 (8)	8 (3)	3.17	1.40-7.18	ns
	lukF	599 (100)	596 (99)	4.02	0.45-36.07	ns	300 (100)	297 (99)	0.99	0.98-1.00	ns
	lukS	585 (98)	510 (85)	6.88	3.93-12.04	ns	293 (98)	244 (81)	9.61	4.30-21.46	ns
	hlgA	597 (100)	595 (99)	1.67	0.40-7.03	ns	299 (100)	296 (99)	4.04	0.45-36.37	ns
	<b>lukF.PV</b>	<b>15 (3)</b>	<b>272 (45)</b>	<b>0.03</b>	<b>0.02-0.05</b>	<b>&lt;0.0001</b>	<b>15 (5)</b>	<b>187 (62)</b>	<b>0.03</b>	<b>0.02-0.06</b>	<b>&lt;0.0001</b>
	<b>lukS.PV</b>	<b>15 (3)</b>	<b>273 (46)</b>	<b>0.03</b>	<b>0.02-0.05</b>	<b>&lt;0.0001</b>	<b>15 (5)</b>	<b>188 (63)</b>	<b>0.03</b>	<b>0.02-0.06</b>	<b>&lt;0.0001</b>
Immune evasion	lukM	1 (0)	0 (0)	n/a			0 (0)	0 (0)	n/a		
	<b>lukD</b>	<b>331 (55)</b>	<b>424 (71)</b>	<b>0.51</b>	<b>0.40-0.65</b>	<b>0.004</b>	<b>166 (55)</b>	<b>215 (72)</b>	<b>0.49</b>	<b>0.35-0.69</b>	<b>ns</b>
	<b>lukE</b>	<b>326 (54)</b>	<b>435 (73)</b>	<b>0.45</b>	<b>0.36-0.57</b>	<b>&lt;0.0001</b>	<b>166 (55)</b>	<b>220 (73)</b>	<b>0.45</b>	<b>0.32-0.63</b>	<b>0.08</b>
	hla	597 (100)	598 (100)	0.67	0.11-4.0	ns	297 (99)	300 (100)	n/a		
	hlb	423 (71)	351 (59)	1.70	1.33-2.15	ns	223 (74)	185 (62)	1.8	1.27-2.55	ns
	hld	600 (100)	600 (100)	n/a			300 (100)	300 (100)	n/a		
	etA	24 (4)	39 (7)	0.60	0.36-1.01	ns	9 (3)	19 (6)	0.46	0.20-1.03	ns
	etB	7 (1)	21 (4)	0.33	0.14-0.78	ns	4 (1)	12 (4)	0.32	0.10-1.02	ns
	etD	17 (3)	21 (4)	0.80	0.42-1.54	ns	9 (3)	10 (3)	0.90	0.36-2.24	ns
	sak	466 (78)	477 (80)	0.90	0.68-1.18	ns	243 (81)	246 (82)	0.94	0.62-1.41	ns
	chp	353 (59)	311 (52)	1.33	1.06-1.67	ns	173 (58)	134 (45)	1.69	1.22-2.33	ns
	scn	552 (92)	589 (98)	0.21	0.11-0.42	ns	276 (92)	298 (99)	0.08	0.02-0.33	ns
<b>edinA</b>	<b>2 (0)</b>	<b>26 (4)</b>	<b>0.07</b>	<b>0.02-0.31</b>	<b>0.001</b>		<b>2 (1)</b>	<b>13 (4)</b>	<b>0.15</b>	<b>0.03-0.66</b>	<b>ns</b>
	<b>edinB</b>	<b>18 (3)</b>	<b>103 (17)</b>	<b>0.15</b>	<b>0.09-0.25</b>	<b>&lt;0.0001</b>	<b>10 (3)</b>	<b>67 (22)</b>	<b>0.12</b>	<b>0.06-0.24</b>	<b>&lt;0.0001</b>
	edinC	5 (1)	16 (3)	0.31	0.11-0.84	ns	3 (1)	8 (3)	0.37	0.09-1.40	ns

	ACME total	2 (0)	2 (0)	1.00	0.14-7.12	ns	2 (1)	2 (1)	1.00	0.14-7.15	ns
Proteases	<b>isaB</b>	<b>371 (62)</b>	<b>529 (88)</b>	<b>0.22</b>	<b>0.16-0.29</b>	<b>&lt;0.0001</b>	<b>184 (61)</b>	<b>287 (96)</b>	<b>0.07</b>	<b>0.04-0.13</b>	<b>&lt;0.0001</b>
	mprF	528 (88)	482 (80)	1.80	1.30-2.47	ns	273 (91)	237 (79)	2.69	1.66-4.36	ns
	aur	553 (92)	585 (98)	0.30	0.17-0.55	ns	278 (91)	296 (99)	0.17	0.06-0.50	ns
	splA	338 (56)	397 (66)	0.66	0.52-0.83	ns	167 (56)	194 (65)	0.69	0.49-0.95	ns
	<b>splB</b>	<b>335 (56)</b>	<b>434 (72)</b>	<b>0.48</b>	<b>0.38-0.62</b>	<b>0.001</b>	<b>166 (55)</b>	<b>222 (74)</b>	<b>0.44</b>	<b>0.31-0.61</b>	<b>ns</b>
	splE	318 (53)	232 (39)	1.79	1.42-2.25	0.003	144 (48)	107 (36)	1.67	1.20-2.31	ns
	sspA	599 (100)	598 (100)	2.00	0.18-22.15	ns	299 (100)	299 (100)	1.00	0.06-16.06	ns
Capsule and Biofilm Genes	sspB	599 (100)	599 (100)	1.00	0.06-16.03	ns	299 (100)	300 (100)	n/a		
	sspP	598 (100)	599 (100)	0.5	0.05-5.52	ns	299 (100)	300 (100)	n/a		
	cap 5	224 (37)	237 (40)	0.91	0.875-1.393	ns	126 (42)	107 (36)	1.31	0.94-1.81	ns
	cap 8	376 (63)	362 (60)	1.10	0.72-1.14	ns	174 (58)	193 (64)	0.77	0.55-1.06	ns
	icaA	600 (100)	598 (100)	n/a		ns	300 (100)	298 (99)	n/a		
Adhesins	icaC	597 (100)	514 (86)	33.30	10.47-105.91	ns	298 (99)	243 (81)	34.95	8.45-144.62	ns
	icaD	600 (100)	596 (99)	n/a		ns	300 (100)	298 (99)	n/a		
	bbp total	543 (91)	575 (96)	0.41	0.26-0.67	ns	271 (90)	286 (95)	0.46	0.24-0.89	ns
	clfA total	600 (100)	600 (100)	n/a		ns	300 (100)	300 (100)	n/a		
	clfB	597 (100)	600 (100)	n/a		ns	299 (100)	300 (100)	n/a		
	cna	284 (47)	321 (54)	0.78	0.62-0.98	ns	148 (49)	170 (57)	0.75	0.54-1.03	ns
	ebh	553 (92)	594 (99)	0.12	0.05-0.28	ns	270 (90)	299 (100)	0.03	0.004-0.22	ns
	ebpS	599 (100)	597 (100)	3.01	0.31-29.02	ns	300 (100)	298 (99)	n/a		
	eno	600 (100)	599 (100)	n/a		ns	300 (100)	299 (100)	n/a		
	fib	372 (62)	448 (75)	0.55	0.43-0.71	ns	184 (61)	231 (77)	0.47	0.33-0.68	ns
	fnbA total	594 (99)	592 (99)	1.34	0.46-3.88	ns	298 (99)	298 (99)	1.00	0.14-1.15	ns
	fnbB total	522 (87)	587 (98)	0.15	0.08-0.27	ns	262 (87)	294 (98)	0.14	0.06-0.34	ns
	<b>map total</b>	<b>582 (97)</b>	<b>494 (82)</b>	<b>6.94</b>	<b>4.15-11.60</b>	<b>0.02</b>	<b>290 (97)</b>	<b>233 (78)</b>	<b>8.34</b>	<b>4.20-16.57</b>	<b>ns</b>
	<b>sasG</b>	<b>253 (42)</b>	<b>370 (62)</b>	<b>0.4</b>	<b>0.36-0.57</b>	<b>&lt;0.0001</b>	<b>134 (45)</b>	<b>161 (54)</b>	<b>0.7</b>	<b>0.51-0.96</b>	<b>ns</b>
	sdrC..total.	595 (99)	518 (86)	18.84	7.58-46.82	ns	296 (99)	243 (81)	17.36	6.2-48.52	ns
	sdrD	527 (88)	555 (93)	0.59	0.40-0.87	ns	265 (88)	278 (93)	0.60	0.34-1.05	ns
	vwb..total.	599 (100)	599 (100)	1.00	0.06-16.03	ns	300 (100)	300 (100)	n/a		

NB: in bold are targets with a >2-fold or <0.5-fold, statistically different OR of target recognition when comparing German versus African isolates.

Table S2: Rates of *in vitro* antibiotic resistance of *Staphylococcus aureus* from colonization and infection in Africa and Germany

Source	Antimicrobial agent	Resistant isolates, % (n)		p value
		Africa (n=300)	Germany (n=300)	
Colonization	Cefoxitin	2.3% (7)	0.7% (2)	ns
	Tetracycline	35.6% (107)	8% (24)	<0.001
	Erythromycin	20.3% (61)	15.7% (47)	ns
	Clindamycin	4.7% (14)	12.7% (38)	0.005
	Gentamicin	5% (15)	0.3% (1)	0.006
	Trimethoprim-sulfamethoxazole	18.3% (55)	0.3% (1)	<0.001
Infection	Cefoxitin	3.3% (10)	7.3% (22)	ns
	Tetracycline	49.7% (149)	5.7% (17)	<0.001
	Erythromycin	18.7% (56)	19.7% (59)	ns
	Clindamycin	3.7% (11)	14.3% (43)	<0.001
	Gentamicin	1% (3)	2.6% (8)	ns
	Trimethoprim-sulfamethoxazole	19.2% (58)	1.3% (4)	<0.001

NS=not statistically significant